Mepolizumab and Eosinophil-Mediated Disease

E-ISSN： 1875-533x|16|36|4774-4778

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.16, Iss.36, 2009-12, pp. : 4774-4778

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Mepolizumab shows potential in hypereosinophilia

Inpharma, Vol. 1, Iss. 1630-1631, 2008-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Efficacy and safety of etanercept in chronic immune-mediated disease

By Murdaca Giuseppe Spanò Francesca Contatore Miriam Guastalla Andrea Magnani Ottavia Puppo Francesco

Expert Opinion on Drug Safety, Vol. 13, Iss. 5, 2014-05 ,pp. : 649-661

Informa Healthcare

Access to resources Recommend Favorite

Mechanisms of Neutrophil-mediated Disease: Innovative Therapeutic Interventions

Current Pharmaceutical Design, Vol. 18, Iss. 12, 2012-04 ,pp. : 1609-1619

Bentham Science Publishers

Access to resources Recommend Favorite

Mepolizumab: First report of recurrent pneumonia and squamous cell carcinoma: case report

Reactions Weekly, Vol. 1, Iss. 1329, 2010-01 ,pp. : 25-26

Adis International

Access to resources Recommend Favorite

Pharmacokinetics and Pharmacodynamics of Mepolizumab, an Anti-Interleukin-5 Monoclonal Antibody

By Smith Deborah A.

Clinical Pharmacokinetics, Vol. 50, Iss. 4, 2011-04 ,pp. : 215-227

Adis International

Access to resources Recommend Favorite